CTRI/2022/02/040223招募中1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Food effect, Pharmacodynamic and Pharmacokinetic Study of Escalating Single and Multiple Doses of PDP-117 in Healthy Subjects.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Able to understand and comply with study specific restrictions and prohibitions. Able to understand and give voluntary written informed consent for participation in the trial before initiation of any study procedure. Healthy, adult, human subjects aged 18 to 45 years (both inclusive) at the time of screening. Male subject who is non-sterilized and sexually active with a female partner, agree to use a suitable and effective double barrier contraceptive method (e.g. a condom and diaphragm) for entire duration of the study and until 120 days after the last dose of study drug. Female subjects of child bearing potential who agree to use a suitable and effective double barrier contraceptive method (e.g. a condom and diaphragm) for entire duration of the study and until 120 days after the last dose of study drug. Female subjects who are of child bearing potential and are surgically sterilized at least 6 months prior to study participation. Female subjects who are tested negative for urine pregnancy test at the time of screening and serum pregnancy test prior to check-in. Female subjects who has surgically sterilized partner (for at least 6 months). Female subjects who are post-menopausal for at least 2 years.
排除标准
- •Subject who received any investigational product within 90 days prior to the first dose of study drug. Subject with an immediate family member as NCS employee, or is in a dependent relationship with a NCS employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress. Subject with history or presence of any markedly abnormal illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine or psychiatric, disease or disorder or other abnormality which may affect safety or can potentially reduce drug clearance (example, renal or hepatic insufficiency). Subject having any markedly abnormal laboratory value or electrocardiogram (ECG) at screening or check-in or having Alanine transaminase (ALT) and/or Aspartate aminotransferase (AST) >1.5 upper limit of normal (ULN) at screening or check-in. Subject with a known hypersensitivity to any component of the formulation of PDP-117. Subjects with hypersensitivity to chickpeas or peanut. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria. Ingestion of any medicine at any time within 4 weeks prior to check-in. Subject with positive result for COVID-19 test done before check-in. Subject with a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or a known history of human immunodeficiency virus (HIV) infection at screening. Subject with a positive history for drugs of abuse (defined as any illicit drug use) at screening or check-in, or a history of alcohol abuse within 1 month prior to screening or is unwilling to agree to abstain from alcohol and drugs throughout the study. Positive result from the urine drug screening and/or alcohol breath analysis done at screening and/or check-in. Subject who has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) for at least 48 hours prior to check-in. Subject who has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to first dose of study drug. Subject with blood pressure outside the ranges i.e. systolic BP (greater than 140 or ââ?°Â¤90 mmHg) and diastolic BP (ââ?°Â¤50 to > 90 mmHg) at the time of screening. If out of range, assessment may be repeated once for eligibility determination at the time of screening and/or check-in. Has a resting heart rate outside the range of 50 to 90 bpm (not on ECGs) at the time of screening. If out of range, the assessment may be repeated once for eligibility determination at the time of screening and/or check-in. Difficulty in swallowing capsules and/or tablets. Female subjects who are taking warfarin or aspirin. Female subjects demonstrating a positive pregnancy screen or currently breast-feeding.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy ParticipantsUlcerative colitisIBDNL-OMON47984Janssen-Cilag International NV98
已完成
1 期
A First-in-Human Phase 1 Study to evaluate the Safety and Tolerability of Single ascending doses of GSBR-1290 in Healthy Adult participants.Type 2 Diabetes MellitusACTRN12622000084785Gasherbrum Bio Pty Ltd. (Australian entity of ShouTi Inc)48
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX105 in Normal Healthy VolunteersNeurological- and autoimmune disorders1000381610029305NL-OMON53467Annexon, Inc.48
终止
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.This current study is being conducted in healthy volunteers to learn about the way this drug behaves in the body when it is given at different doses. The study will also be conducted in patients with Hepatitis C genotype 1.Infection - Other infectious diseasesACTRN12614000304639Achillion Pharmaceuticals, Inc157
已完成
1 期
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882 in Healthy Adult Male VolunteersHyperuricemiaACTRN12619000908134Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.30